企業プロフィール · Healthcare

Hikma Pharmaceuticals PLC

HIK · LSE
国 / 地域
UK
従業員数
9,500
公式サイト
www.hikma.com
Buffett Score
52/100
標準
時価総額£32.71億
売上高(TTM)£34.19億
EBITDA£8.79億
純利益率11.32%
ROE15.41%
PER (TTM)11.88
予想PER8.42
PEG2.38
EPS£0.01
配当利回り5.47%
52週レンジ£11.35 – £17.83

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。

この銘柄のレポートはお使いの言語でまだありません。